These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1233238)

  • 1. Plasma concentration of alpha-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester.
    Saavedra JA; Reid JL; Jordan W; Rawlins MD; Dollery CT
    Eur J Clin Pharmacol; 1975 Aug; 8(6):381-6. PubMed ID: 1233238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic disposition and cardiovascular effects of methyldopate in unanesthetized rhesus monkeys.
    Walson PD; Marshall KS; Forsyth RP; Rapoport R; Melmon KL; Castagnoli N
    J Pharmacol Exp Ther; 1975 Oct; 195(1):151-8. PubMed ID: 810574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of methyldopa in man after oral administration of the pivaloyloxyethyl ester.
    Vickers S; Duncan CA; Ramjit HG; Dobrinska MR; Dollery CT; Gomez HJ; Leidy HL; Vincek WC
    Drug Metab Dispos; 1984; 12(2):242-6. PubMed ID: 6144491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects.
    Barnett AJ; Bobik A; Carson V; Korman JS; McLean AJ
    Clin Exp Pharmacol Physiol; 1977; 4(4):331-9. PubMed ID: 908178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alpha-methyldopa on blood pressure in the anaesthetized dog.
    Blower PR; Poyser RH; Robertson MI
    J Pharm Pharmacol; 1976 May; 28(5):437-40. PubMed ID: 6754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of central and peripheral mechanisms in the action of alpha-methyldopa on blood pressure and renin secretion.
    Frankel RJ; Reid IA; Ganong WF
    J Pharmacol Exp Ther; 1977 May; 201(2):400-5. PubMed ID: 323462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa.
    Dobrinska MR; Kukovetz W; Beubler E; Leidy HL; Gomez HJ; Demetriades J; Bolognese JA
    J Pharmacokinet Biopharm; 1982 Dec; 10(6):587-600. PubMed ID: 7182456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of methyldopa on prolactin serum concentration. Comparison between normal and sustained-release formulations.
    Baldini M; Cornelli U; Molinari M; Cantalamessa L
    Eur J Clin Pharmacol; 1988; 34(5):513-5. PubMed ID: 3203713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypotensive activity of S-alpha-methyldopa during long-term (steady-state) intravenous infusions.
    Walson PD; Pesout J; Forsyth RP; Castagnoli N; Melmon KL
    J Pharmacokinet Biopharm; 1976 Oct; 4(5):389-94. PubMed ID: 826619
    [No Abstract]   [Full Text] [Related]  

  • 10. A study of the disposition of alpha-methyldopa in newborn infants following its administration to the mother for the treatment of hypertension during pregnancy.
    Jones HM; Cummings AJ; Setchell KD; Lawson AM
    Br J Clin Pharmacol; 1979 Nov; 8(5):433-40. PubMed ID: 508547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of methyldopa in man.
    Kwan KC; Foltz EL; Breault GO; Baer JE; Totaro JA
    J Pharmacol Exp Ther; 1976 Aug; 198(2):264-77. PubMed ID: 781212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of methyldopa.
    Myhre E; Rugstad HE; Hansen T
    Clin Pharmacokinet; 1982; 7(3):221-33. PubMed ID: 7047042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasma noradrenaline and growth hormone response to alpha-methyldopa and clonidine in hypertensive subjects.
    Struthers AD; Brown MJ; Adams EF; Dollery CT
    Br J Clin Pharmacol; 1985 Mar; 19(3):311-7. PubMed ID: 3986086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants.
    White WB; Andreoli JW; Cohn RD
    Clin Pharmacol Ther; 1985 Apr; 37(4):387-90. PubMed ID: 3838502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of systemic and central administration of alpha-methyldopa.
    Forsyth RP; Bolme P; Ishizaki T; Melmon KL
    J Pharmacol Exp Ther; 1978 Jun; 205(3):675-82. PubMed ID: 96250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disposition of methyldopa in hypertensive and renal-insufficient children.
    O'Dea RF; Mirkin BL
    Clin Pharmacol Ther; 1980 Jan; 27(1):37-43. PubMed ID: 7351116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of conjugation and drug elimination in the human neonate.
    Cummings AJ; Whitelaw AG
    Br J Clin Pharmacol; 1981 Oct; 12(4):511-5. PubMed ID: 6117307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of methyldopa in the rat. Role of 3-O-methylated metabolites.
    Zavisca FG; Breau AP; Wurtman RJ
    Circ Res; 1979 Nov; 45(5):684-90. PubMed ID: 487531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive high-performance liquid chromatographic assay using electrochemical detection for a novel prodrug ester of methyldopa, pivaloyloxyethyl 3-(3,4-dihydroxyphenyl)-2-methylalaninate, in plasma and urine.
    Musson DG; Vincek WC; Dobrinska MR; Vickers S; Leidy HL
    J Chromatogr; 1984 Jun; 308():251-9. PubMed ID: 6746818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy of alpha-methyldopa, chlorothiazide and Supres-150 (alpha-methyldopa-chlorothiazide).
    Fernandez PG; Zachariah PK; Bryant DG; Missan SS
    Can Med Assoc J; 1980 Aug; 123(4):284-7. PubMed ID: 7020900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.